Longevity Therapeutics

Statin development is presented as a precedent for using biomarkers to compress clinical trials. Direct human lifespan trials are described as impractical for proving large lifespan extension. Aging clocks may eventually become accepted biomarkers for predicting multimorbidity risk. A mechanism that works across multiple age-related diseases could support broader use through existing regulatory mechanisms. The practical drug-development path targets recognized diseases before seeking broader aging-related uses.